Search

Elixir Medical Corporation Announces Excellent Six-Month Safety and Efficacy Results for Thin-Strut DESolve Cx Novolimus Eluting Bioresorbable Coronary Scaffold System

Sunnyvale, CA —October 31, 2016—Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today that a successful live case demonstration of its next-generation DESolve® NXT Plus Novolimus Eluting Bioresorbable Coronary Scaffold System was presented at the 28th annual Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, DC. “This live demonstration presented […]

Successful Live Case Demonstration of Elixir Medical’s Fully Bioresorbable DESolve NXT Plus Novolimus Eluting Coronary Scaffold System at TCT

Sunnyvale, CA —October 31, 2016—Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today that a successful live case demonstration of its next-generation DESolve® NXT Plus Novolimus Eluting Bioresorbable Coronary Scaffold System was presented at the 28th annual Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, DC. “This live demonstration presented […]

Elixir Medical Announces Excellent, 3-Year Clinical and Imaging Results for the CE-Marked Fully Bioresorbable DESolve Novolimus Eluting Coronary Scaffold System

Golden Tube Visualization, Low MACE and Lumen Gain Sustained Long-Term Sunnyvale, Calif. – October 15, 2015 — Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced excellent 3-year clinical and imaging results from the DESolve Nx international pivotal clinical trial for the CE Mark-approved, fully bioresorbable DESolve® Novolimus Eluting Coronary Scaffold System. […]

Elixir Medical Announces Excellent, 3-Year Imaging Results for the CE-Marked Fully Bioresorbable DESolve Novolimus Eluting Coronary Scaffold System

Successful Live Case of DESolve® 100 implantation at Elixir Symposium at EuroPCR 2015 Sunnyvale, Calif. – May 20, 2015 — Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced excellent 3-year imaging results from the DESolve Nx international pivotal clinical trial for the CE Mark-approved, fully bioresorbable DESolve® Novolimus Eluting Coronary Scaffold […]

This site is registered on wpml.org as a development site. Switch to a production site key to remove this banner.